Oryzon Genomics Rises 3% After Progress in a Clinical Study of Leukemia

Oryzon Genomics rose more than 3% on the stock market on Monday, September 9th, after two o’clock in the afternoon, after announcing progress in a clinical study of leukemia. Specifically, the shares of the Spanish biopharmaceutical company rose 3.19% on the Continuous Market, trading at a price of 1.8 euros.

The first patient has been recruited and has already received the first dose in a Phase Ib dose-finding trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with venetoclax and azacitidine in first-line acute myeloid leukemia (AML), the company reported in a statement.

This is an investigator – initiated clinical trial sponsored by Oregon Health & Science University (OHSU) Knight Cancer Institute in the United States. Led by Dr. Curtis Lachowiez of OHSU, this study (NCT06357182) will evaluate the safety, tolerability, and optimal dosing of iadademstat when administered with venetoclax and azacitidine, the standard of care, in patients with newly diagnosed AML. The trial will also evaluate the preliminary efficacy of the triple combination .

“Given the activity observed with LSD1 inhibitors in combination with azacitidine in AML, testing a triple combination including iadademstat with the current standard of care azacitidine+venetoclax is a logical next step to try to improve the outlook for patients living with AML, if the combination is shown to be safe and active,” said Lachowiez, Principal Investigator of the study.

Oryzon Genomics presented favourable results from another trial at the European Hematology Association (EHA) congress

“This trial builds on the positive results obtained in our Alice trial in first-line AML, where the combination of iadademstat with azacitidine showed strong antileukemic activity with deep and durable responses and a manageable safety profile, even in patients with high-risk prognostic factors who respond poorly to venetoclax+azacitidine,” added Carlos Buesa, CEO of Oryzon.

In the AML setting, iadademstat is also being evaluated in a Phase Ib trial sponsored by Oryzon in combination with gilteritinib in patients with relapsed/refractory AML harboring a FMS-like tyrosine kinase mutation (FLT3mut+). This Frida trial is being conducted in the United States.

Frida’s preliminary results from the first two cohorts were recently presented at the European Hematology Association (EHA) 2024 congress in June. These results demonstrated that the combination of iadademstat plus gilteritinib was safe and well tolerated, and had encouraging antileukemic activity, according to the spin-off from the University of Barcelona (UB).

__

(Featured image by Joshua Mayo via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us